| Autor: |
Britta Maurer, Schietzel S, Born A, Cédric Hirzel, Daniel Sidler, Matthias B. Moor, Michael P. Horn, Anderegg M, Andreas Limacher |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.09.30.21264335 |
| Popis: |
BackgroundImmune responses upon SARS-CoV-2 vaccination in patients receiving anti-CD20 therapies are impaired but vary considerably. We conducted a systematic review and meta-analysis of the literature on SARS-CoV-2 vaccine induced humoral and cell-mediated immune response in patients previously treated with anti-CD20 antibodies.MethodsWe searched PubMed, EMBASE, Medrxiv and SSRN using variations of search terms “anti-CD20”, “vaccine” and “COVID” and included original studies up to August 21st,2021. We excluded studies with missing data on humoral or cell-mediated immune response, unspecified methodology of response testing, unspecified timeframes between vaccination and blood sampling or low number of participants (≤ 3). We excluded individual patients with prior SARS-CoV-2 infection or incomplete vaccine courses. Primary endpoints were humoral and cell-mediated immune response rates. Pre-specified subgroups were time of vaccination after anti-CD20 therapy (< vs > 6 months), time point of response testing after vaccination (< vs > 4 weeks) and disease entity (autoimmune vs cancer vs renal transplant). We used random-effects models of proportions.FindingsNinety studies were assessed. Inclusion criteria were met by 23 studies comprising 1342 patients. Overall rate of humoral response was 0.41 (95% CI 0.35 – 0.47). Overall rate of cell-mediated immune responses was 0.71 (95% CI 0.47 – 0.90). Longer time interval since last anti-CD20 therapy was associated with higher humoral response rates > 6 months 0.63 (95% CI 0.53 – 0.72) vs < 6 months 0.2 (95% CI 0.03 – 0.43); p = 0.001. Compared to patients with haematological malignancies or autoimmune diseases, anti-CD20 treated kidney transplant recipients showed the lowest vaccination response rates.InterpretationPatients on anti-CD20 therapies can develop humoral and cell-mediated immune responses after SARS-CoV-2 vaccination, but subgroups such as kidney transplant recipients or those with very recent B-cell depleting therapy are at high risk for non-seroconversion and should be individually assessed for personalized SARS-CoV-2 vaccination strategies. Potential limitations are small patient numbers, heterogeneous diseases and assays used.FundingThis study was funded by Bern University Hospital. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
